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The increasing world demand for human biologics cannot
be met by current production platforms based primarily on
mammalian cell culture due to prohibitive cost and limited
scalability [1]. Recent progress in plant expression vector
development, downstream processing, and glycoengineering
has established plants as a superior alternative to biologic
production [2–4]. Plants not only offer the traditional advan-
tages of proper eukaryotic proteinmodification, potential low
cost, high scalability, and increased safety but also allow the
production of biologics at unprecedented speed to control
potential pandemics or with specific glycoforms for better
efficacy or safety (biobetters) [5, 6]. The approval of the first
plant-made biologic (PMB) by the United States Food and
Drug Administration (FDA) for treating Gaucher’s disease
heralds a new era for PMBs and sparks new innovations in
this field [7, 8].
This special issue aims to showcase the recent develop-
ments and application of PMBs in areas of plant host systems,
expression vectors, novel vaccine candidates, glycoengineer-
ing and posttranslationalmodification, and economic impact
and evaluation. Eight original research and review articles
among submissions are selected for this special issue.
Manufacturing costs are a prime determinant of the
market acceptability, availability, and profitability of the
product for its manufacturer. One of the potential tradi-
tional advantages of plant-based systems is their ability to
lower the production cost of recombinant biologics. Lower
manufacturing costs have been widely assumed as an innate
feature of plant-based production platforms because they
forego the need for capital investments to build sophisticated
cell culture facilities and expensive culture media for biomass
generation. However, information on the actual costs of
producing PMB at industrial scale is not readily available
and reports of serious studies in this area are scarce in the
scientific literature. Thus, accurately documenting such an
advantage is crucial for plant-based systems to be recognized
as a serious platform for manufacturing protein biologics.
Tuse´ et al. provided such an important study in this issue.
They reported two case studies on plant-made enzymes. One
focused on human butyrylcholinesterase (BuChE) produced
in greenhouse-cultivatedNicotiana plants for use as amedical
countermeasure and the other on cellulases produced with
plants grown in the field for ethanol production as a fuel
extender. Using reported data and SuperPro Designer mod-
eling software, the authors examined process unit operations
and estimated the bulk active product and per-dose or per-
unit costs. Their analyses demonstrate that a plant-based
platform can substantially reduce the cost of these enzymes
compared with traditional platforms. For example, the unit
production costs for the plant-made BuChE are calculated
to be approximately $234 or $474 per dose, respectively,
dependent on whether or not facility dependent costs are
included in the estimation. This is in stark contrast to
the ∼$10,000/dose production cost estimated for blood-
derived BuChE. Similarly, the study concludes that for the
cellulase enzyme, using the plant-based system may result
in a >30% reduction in unit production costs and an 85%
reduction in the required capital investment compared with
the current fungal-based system.The authors did caution that
the cost advantages of PMBs are molecule/product-specific
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and dependent upon the cost improvement of alternative
production platforms. This report presents case studies of
PMBs for diverse applications and provides urgently needed
technoeconomic evaluations of the current PMB platform.
Two of the original research papers report on the develop-
ment of plant-made vaccines against infectious diseases.He et
al. report their findings of using the domain III (DIII) ofWest
Nile virus (WNV) envelope protein as a vaccine candidate for
WNV.They found thatN. benthamiana plants could produce
this antigen efficiently. They also showed the advantage of
plant-derived DIII in downstream processing; unlike the
insolubleWNVDIII produced in E. coli, plant-derivedDIII is
soluble and readily enriched to high purity without the need
for denaturing and refolding. Furthermore, plant-produced
DIII was shown to evoke a potent DIII-specific humoral
response in mice. No vaccine against WNV is currently
available for human use and this study presents an effort
towards developing efficacious vaccines against this virus.
Another paper in this category investigated the possibility
of developing a plant-based vaccine against norovirus Narita
104 (Na) using virus-like particles (VLPs) assembled from
the capsid protein (NaVCP). The results showed that expres-
sion of NaVCP caused severe leaf necrosis that limited its
accumulation in plants. However, plant-produced VLPs were
observed by microscopy and induced mucosal and serum
antibody responses in mice when delivered intranasally. The
authors proposed that Narita 104 VLPs could be a component
of a multivalent subunit vaccine.
Downstream processing of target proteins represents a
major cost for the overall cost of goods in PMB production.
Therefore, reducing cost of PMB extraction and purifi-
cation will facilitate the commercialization of plant-based
production platform and products. A paper in this issue
reports an alternative way to extract protein from plants.
Instead of homogenization of plant tissue, the authors used
a technique called vacuum infiltration-centrifugation (VI-C)
to isolate recombinant proteins that are targeted for secretion.
Their results indicated that three rounds of VI-C recovered
97% of the secreted proteins accessible to the procedure.
While the VI-C procedure was successful for a truncated E1
endoglucanase, the full length E1 enzyme was not recovered
as efficiently by the same procedure, indicating the method’s
limitation on the size of target proteins or the need for
technical optimization. However, this study does represent
an alternative downstream process for recovering secreted
proteins from plant tissue (apoplast) that can potentially
drastically reduce the production cost.
Several review articles are also included in this spe-
cial issue. Two of them discuss the new plant hosts and
expression strategies for PMB production and compare them
with other alternative manufacturing systems. Hudson et
al. report the use of soybean seeds for the expression of
a nontoxic form of S. aureus enterotoxin B (mSEB). As a
natural protein source, soybean seeds allow for an extended
storage time under ambient conditions and, thus, can facil-
itate a more flexible processing schedule. The study results
demonstrated an impressive production of ∼76 theoretical
doses of human vaccine per single soybean seed. Merlin et
al. present a comprehensive review of different production
strategies applied to four well-characterized, yet very diverse
PMBs. The authors emphasize that plant-based production
platforms represent a whole array of different strategies that
need to be carefully evaluated, in terms of not only mere
product yield, but also product quality, production scalability,
costs, and cGMP compliance. For a given PMB, the optimal
pairing of a plant production host with the most appropriate
expression and/or downstream processing strategy often
determines its ultimate success. The four case studies center
on four different classes of biologics: (i) human glutamic
acid decarboxylase (hGAD65), a promising candidate for
treating autoimmune type 1 diabetes, (ii) Norwalk VLPs
assembled from the Norwalk virus coat protein VP1 for
vaccine development, (iii)monoclonal antibody (mAb) 2G12,
an anti-HIV-1 human IgG1, a potential human therapeutics
against HIV, and (iv) human interleukin-6 (hIL-6), a secreted
glycoprotein belonging to the cytokine family. Production
of these biologics with various plant systems and expression
strategies is examined. The plant systems range from leaf-
based production (tobacco,N. benthamiana, lettuce, andAra-
bidopsis) to seeds (tobacco, Arabidopsis, maize, and petunia),
fruits (tomato), and tubers (potato), with both stable and
transient expression approaches.Moreover, the production of
the fourth-mentioned biologics in plant systems is compared
with that of traditional fermenter-based systems such as E.
coli, yeast,mammalian, and insect cells.The authors highlight
the advantages of plant-based systems over fermenters, par-
ticularly for certain niche markets. They conclude that plant-
based platforms are most beneficial for the production of
biologics that require high quantity, rapid production speed,
complex post-translational modifications, or oral delivery.
Recent vector development for PMBs is also discussed.
Recognizing the potential pitfalls of recombinant protein
production in stably transformed plants, a concise review
on the novel transient expression systems based on the use
of plant virus expression vectors is presented. The author
concludes that transient expression systems can overcome the
challenges associatedwith systems based on transgenic plants
such as low protein accumulation and long development
time, and they can reduce the potential risk of transgene
spread from transgenic plants to other plants in the environ-
ment and thus alleviate the public concerns.
Overall, the papers in this special issue highlight the
recent progress in the PMB field. It is our hope that these
papers will provide pertinent information for not only the
PMB community, but also the overall scientific and business
community for the further consideration and acceptance of
plant-based systems as a viable platform for the development
and manufacture of human biologics.
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